Novartis Secures Positive EU Committee Opinion on Rydapt

Novartis Secures Positive EU Committee Opinion on Rydapt

Swiss drug maker Novartis AG said Friday morning that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended approval of Rydapt for treating adults with newly-diagnosed acute myeloid leukemia who are FLT3 mutation-positive. If approved by the European Commission, the oral, multi-targeted inhibitor of multiple kinases would represent the first targeted treatment for newly diagnosed FLT-3 mutated AML in the EU. […]

Read More ˃